RecruitingACTRN12622001537741

Cognitive decline in cancer: A cross-sectional study

Cancer-related cognitive impairment: Investigating cognition, psychosocial factors, and neurogenesis biomarkers.


Sponsor

Curtin University

Enrollment

200 participants

Start Date

Nov 3, 2023

Study Type

Observational

Conditions

Summary

This study is investigating cancer-related cognitive impairment, and the impact of a cognitive training intervention. Who is it for? You may be eligible for this study if you are aged 18 years or over, living in or near the Perth/Peel regions of Western Australia, and are currently undergoing any treatment for a confirmed diagnosis of cancer. This study also needs healthy controls; that is, people aged 18 years or over, living in or near Perth/Peel regions of Western Australia, with no cancer diagnosis and no history of any cancer diagnosis. Study details Participants will be asked to complete tests of memory, attention, executive function, and processing speed, as well as other psychological factors such as quality of life, sleep, anxiety, and pain. Biological markers implicated in neurogenesis will be assessed through blood tests, direct questions, and with reference to medical history. After which, researchers will contact you if you are eligible for the second part of the study. It is hoped that findings from this study will assist researchers with optimising daily oncology care.


Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

"Chemo brain" — the cognitive fog and memory difficulties that some people experience during or after cancer treatment — is a well-documented but poorly understood phenomenon. This cross-sectional study is investigating how common cognitive impairment is among people with cancer in the Perth and Peel regions of Western Australia, and exploring the biological and psychological factors that might explain it. Participants will complete a series of tests assessing memory, attention, processing speed, and executive function (planning and problem-solving), alongside questionnaires about quality of life, sleep, anxiety, and pain. Blood samples will also be taken to look at biological markers related to brain health. The study also involves healthy volunteers with no cancer history as a comparison group, to establish what typical cognitive performance looks like. You may be eligible if you are 18 or older, live in or near the Perth/Peel region of Western Australia, have a confirmed cancer diagnosis that does not involve the central nervous system (brain or spinal cord), and are currently undergoing any form of treatment. Healthy adults with no history of cancer may also participate as controls. You would not be eligible if you have a pre-existing cognitive or developmental condition, a neurodegenerative disease, are pregnant, or have central nervous system metastases.

This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Brief name: cross-section This observational study involves a large cross-section of non-CNS cancer patients and demographic matched healthy controls. Variables collected include cognitive performa

Brief name: cross-section This observational study involves a large cross-section of non-CNS cancer patients and demographic matched healthy controls. Variables collected include cognitive performance, psychosocial functioning, medical history, apolipoprotein genotype, and peripheral plasma brain-derived neurotrophic factor (BDNF) levels. The mode of observation will be a single 90-120 minute visit to the study clinic per participant, at a single timepoint of data collection. This is noninclusive of preliminary screening and liaising with potential participants.


Locations(1)

WA, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12622001537741


Related Trials